Novo Nordisk’s Rare Disease Unit Expects Breakthrough in Sickle Cell Treatment

Novo Nordisk is advancing etavopivat for sickle cell disease, aiming to reduce vaso-occlusive crises (VOCs) by 50% in a Phase 3 trial next year. The drug came from Novo’s $1.1 billion buyout of Forma Therapeutics. If successful, etavopivat could fill a market gap left by the withdrawal of other sickle cell treatments. Novo sees this as a key investment in its growing rare disease unit.

At OxyDial, we understand the critical need for innovative sickle cell therapies. With millions affected globally, particularly in underserved regions, new treatments like etavopivat offer hope for better outcomes. We remain optimistic that ongoing research will bring transformative solutions to patients who need them most.